The firm’s invoiced sales for the quarter ended 31 March 2021 were $2,744,000; a 188% increase.
As yet there are no proven treatments for long-COVID symptoms and given the number of people likely to be afflicted before this pandemic is done, there is a growing need for appropriate treatments.
As for the current quarter and looking further ahead, among its activities Bod intends finalising its registration strategy for new Schedule 3 CBD products in the Australian market.